Will any FDA-approved GLP-1 agonists be withdrawn from the market for safety reasons by 01/01/2025?
Plus
14
Ṁ946Jan 1
12%
chance
1D
1W
1M
ALL
GLP-1 agonists, such as semaglutide (ozempic/wegovy), tirzepatide (mounjaro), and dulaglutide (Trulicity), are becoming popular for weight loss and Type-2 diabetes treatment. This market resolves positively if any approved GLP-1 agonists for either T2D or weight loss are withdrawn from the market due to safety reasons by the listed date. This applies either if the FDA mandates it or if the company withdraws the drug voluntarily.
This question is managed and resolved by Manifold.
Get
1,000and
3.00
1,0003.00Sort by:
made a market that breaks this out by end year and added a M5k subsidy: https://manifold.markets/AndyMartin/m5k-subsidy-will-any-fdaapproved-gl
Related questions
Related questions
[M$5k subsidy] Will any FDA-approved GLP-1 agonists be withdrawn from the market for safety reasons by...
Will a GLP-1 agonist diabetes / weight loss drug be the top bestselling drug in 2025?
30% chance
Will a GLP-1 receptor agonist (Ozempic-like drug) be added to public water supplies in the United States by 2075?
30% chance
Will one of the GLP agonist drugs (eg Semaglutude/Wegovy Tirzepatide/Mounjaro) have a black box warning by 2025
33% chance
What will happen to the GLP-1 / Ozempic compounding pharmacy loophole?
Will a clinical trial reporting weight-loss benefits of a GLP-1 agonist be published in a major medical journal in 2024?
84% chance
Will aducanumab be withdrawn by the FDA by 2025?
45% chance
Reliable Reporting indicating that more than 3% of Americans are taking GLP-1 agonists in 2024
36% chance
Will GLP-1 agonists help stop or reverse the US obesity trend by end of 2027
75% chance
Will Ozempic/GLP-1 Agonists become an issue with a clear partisan divide in the US in the next 5 years?
38% chance